Leadiant Biosciences, Inc.
http://leadiant.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Leadiant Biosciences, Inc.
Chiesi Takes Long View To Build Japan Rare Disease Presence
After expanding its local portfolio through acquisitions and partnerships, Chiesi is now aiming to build its presence in Japan's rare disease sector over the long term, helped by development of global products and possible new alliances.
Medicare Price Inflation Rebates Levied On 27 Part B Drugs In First Round; Pfizer Tops The List
Biden Administration releases first list of Part B drugs subject to inflation rebates; others to follow on quarterly basis. Medicare won’t invoice sponsors until 2025, but patients could see coinsurance reductions next month.
EU Regulatory System Attacked Over Quality Of Approvals
If anyone can throw cold water on the claimed benefits of some of Europe's most recently approved medicines, it’s the international drug bulletin, Prescrire. In an assessment of 108 of the pharma industry’s latest offerings, it gives a cautious welcome to some but says that more than half bring nothing new and others could even be dangerous to patients.
Dutch Hospital Resumes Own Manufacture Of Leadiant’s Costly Drug
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Sigma-Tau HealthScience LLC
- Sigma-Tau PharmaSource Inc.
- Sigma-Tau Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice